Vivos Therapeutics terminates Chief Medical Officer Dr. G. Dave Singh for cause, effective March 1, 2022

Vivos Therapeutics, Inc.

Dr. Singh was terminated for cause per his employment agreement dated October 9, 2020.
He had been on sabbatical since September 2021 as Adjunct Professor at Stanford University.
Company has reallocated his responsibilities to other personnel and expects no significant operational impact.
Dr. Singh is no longer affiliated with Vivos as of March 1, 2022.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. G. Dave Singh

Chief Medical Officer

VVOS · Vivos Therapeutics, Inc.

Effective: 2022-03-01
Filed: March 1, 2022, 6:59 PM ET

provided Dr. G. Dave Singh, the Company’s Chief Medical Officer (“Dr. Singh”), with notice of termination of his employment with the Company “for cause” pursuant to the terms Dr. Singh’s employment agreement with the Company, dated October 9, 2020.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. G. Dave Singh was terminated as Chief Medical Officer at Vivos Therapeutics, Inc..

Action: terminated
Role: Chief Medical Officer

Exact text from the filing

provided Dr. G. Dave Singh, the Company’s Chief Medical Officer (“Dr. Singh”), with notice of termination of his employment with the Company “for cause” pursuant to the terms Dr. Singh’s employment agreement with the Company, dated October 9, 2020.

View on SEC.gov

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-005761

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.